Why SVRA beats the market
Up 307% over five years while the S&P 500 rose 73%; up 9% in the past year.
- Its filed figures weakened while the shares beat the market.
The other side, how the business stands, the timeline, and its peers, for Pro members.
Follow SVRA's trial news. Pro members can get an alert when Savara files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 307% over five years while the S&P 500 rose 73%; up 9% in the past year.
The other side, how the business stands, the timeline, and its peers, for Pro members.
| Holding it back | A $153M loss |
| Latest filing | 10-Q, Nov 9 |
After its last 3 reports it closed +1.9% on average, higher 2 of 3 times.
About 4 quarters
CFO David L Lowrance sold 394,528 shares on Jun 22.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Poorfor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means
SVRA is #71 of 89 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 71 |
Net income over four quarters: SVRA -$153M, INO -$71.1M, AGIO -$373M.
Expected to report Fri Mar 12, after the close (in 116 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| May 12, 2026 | -5.1% | +3.7% | -7.1% |
| Mar 13, 2026 | 0.0% | -1.3% | -3.0% |
| Nov 12, 2025 | +0.5% | +3.4% | +11.7% |
RSI 45.9, MACD above signal, below both averages. Not scored.
One insider sold $2.2M across 1 filing in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: SVRA is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
“The pharmaceutical industry is highly competitive and subject to continuous technological change.”
SVRA scores -4 today, which Breakaway calls Poor. It is #71 of 89 in Pharma by Quality Score, with 1 of 14 chart checks firing. Up 307% over five years while the S&P 500 rose 73%; up 9% in the past year. Cash lasts about 4 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
SVRA scores -4 today, which Breakaway calls Poor (below zero). That is #71 of 89 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind SVRA's -4.
One insider sold $2.2M across 1 filing in the last 6 months. No open-market buys on record. The newest is David L. Lowrance, Chief Financial Officer, who sold $2.2M on Jun 22.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.